Ustekinumab for treating active psoriatic arthritis

  • Technology appraisal guidance
  • TA340
  • Published: 
  • Last updated: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Centre for Reviews and Dissemination and Centre for Health Economics, University of York:

  • Craig D, O'Connor J, Rodgers M et al. Ustekinumab for treating active and progressive psoriatic arthritis: a single technology appraisal, October 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Janssen

II. Professional/expert and patient/carer groups:

  • Psoriasis and Psoriatic Arthritis Alliance

  • Psoriasis Association

  • British Association of Dermatologists

  • British Society for Rheumatology

  • Primary Care Rheumatology Society

  • Royal College of Nursing

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • AbbVie

  • Merck Sharp & Dohme

  • Novartis Pharmaceuticals

  • Pfizer

  • Arthritis Research UK

  • NHS Centre for Reviews and Dissemination and Centre for Health Economics, University of York

  • National Institute for Health Research Health Technology Assessment Programme

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on ustekinumab by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the ACD.

  • Dr Eleanor Korendowych, Consultant Rheumatologist, nominated by British Society for Rheumatology – clinical expert

  • Professor Dennis McGonagle, Professor of Investigative Rheumatology, nominated by Janssen – clinical expert

  • David Chandler, Chief Executive of the Psoriasis and Psoriatic Arthritis Alliance, nominated by Psoriasis and Psoriatic Arthritis Alliance – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Janssen